PipelineReview.com7h
miRecule and GBI Biomanufacturing Announce Strategic Partnership to Advance Development of Antibody RNA Conjugate (ARC) Therapies
PLANTATION, FL, and GAITHERSBURG, MD, USA I January 28, 2025 I miRecule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a ...
PipelineReview.com7h
Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
SOUTH SAN FRANCISCO, CA, USA I8, 2025 I Helicore Biopharma Inc., a biopharmaceutical company focused on the discovery and development of ...
PipelineReview.com7h
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
SOUTH SAN FRANCISCO, CA, USA I8, 2025 I Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the ...
PipelineReview.com7h
Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002
PISCATAWAY, NJ, USA I January 28, 2025 I Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept ...
PipelineReview.com16h
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
Trial anticipated for H2 2025 to evaluate most advanced next generation intranasal pertussis vaccine for whooping cough ...
PipelineReview.com16h
Herantis Pharma: encouraging pharmacokinetic data and first subject with Parkinson’s disease dosed in the Phase 1b trial
I Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce an ...
PipelineReview.com16h
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
SAN FRANCISCO, CA, USA I7, 2025 I GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing ...
PipelineReview.com16h
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium
AUSTIN, TX, USA and HAMILTON, Canada and SAN DIEGO, CA, USA I7, 2025 I Triumvira Immunologics, a clinical-stage company ...
PipelineReview.com1d
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, NY, USA I5, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® ...
PipelineReview.com1d
Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, China I January 26, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its ...
PipelineReview.com1d
AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
LAUSANNE, Switzerland I7, 2025 I AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic ...
PipelineReview.com4d
EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR ™ platform and SCL mRNA technology WEST PALM BEACH, FL, USA I3, 2025 I EXUMA Biotech, Corp., a ...